EGFR and non-small cell lung carcinoma: Therefore, we aimed to identify a panel of circulating plasma microRNAs that can distinguish between NSCLC patients with EGFR-sensitive mutations and EGFR wild-type patients and to explore the potential of this microRNA panel to monitor tumor responses to EGFR-TKI treatment.